The Cigna Group
CI
$298.28
-2.45%
The Cigna Group is a diversified healthcare services company operating two primary segments: Evernorth, a large pharmacy benefit management and specialty pharmacy platform built around the 2018 Express Scripts merger, and Cigna Healthcare, which provides employer-sponsored self-funded medical benefits to roughly 16 million US members plus about 2 million international members. Cigna is best characterized as a scaled, fee-and-spread-driven healthcare platform rather than a pure risk-bearing insurer, with Evernorth's PBM contracts — including the Department of Defense and a multiyear Centene win — anchoring its competitive identity and giving it a distinct position versus managed-care peers. The current investor narrative centers on the durability of Evernorth's growth engine against margin pressure in the legacy insurance business, with the company's April 2026 decision to raise full-year guidance while exiting the individual exchange business and conducting a strategic review of eviCore signaling a deliberate portfolio pivot toward higher-return, less capital-intensive operations. That pivot, combined with a very low beta and a heavily discounted multiple, frames the debate: bulls see a cash-generative, defensive compounder trading at a deep value discount, while bears point to thin net margins, reimbursement pressure across the sector, and execution risk from the non-core divestitures.…
CI
The Cigna Group
$298.28
Related headlines
CI 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Cigna Group's 12-month outlook, with a consensus price target around $342.29 and implied upside of +14.8% versus the current price.
Average Target
$342.29
0 analysts
Implied Upside
+14.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$288 - $400
Analyst target range
Bulls vs Bears: CI Investment Factors
The bull case rests on hard numbers: a 9.17x forward PE, 0.15 PEG, $9.11 billion of TTM free cash flow, 6.6% revenue growth, and an 11.5% average analyst target upside, all wrapped in a 0.298 beta defensive profile. The bear case is equally concrete: 2.17% net margins, a 0.849 current ratio, 12.5 points of 12-month relative underperformance, and sector-wide reimbursement pressure that threatens the PBM spread model. On balance, the evidence currently favors the bulls because the valuation discount is extreme relative to cash generation and the analyst distribution is skewed to the upside, but the margin of safety is thinner than the headline multiple suggests. The single most important tension is whether Evernorth's PBM economics can hold as reimbursement pressure mounts while management divests non-core assets — if Evernorth margins stabilize, the deep-value thesis re-rates; if they compress, the low multiple is a value trap.
Bullish
- Deep value on forward earnings: CI trades at a forward PE of just 9.17x against trailing PE of 12.34x, implying the market expects EPS to roughly double from the $0.08 GAAP figure to the $46.63 consensus estimate. The PEG ratio of 0.15 is among the lowest in large-cap healthcare, signaling the growth embedded in estimates is barely being priced.
- Analyst targets imply 11.5% upside: With 24 analysts covering and a consensus 'buy' rating (mean 1.75), the average target of $342.29 sits 11.5% above the $306.95 current price, and the high target of $400 implies 30.3% upside. Even the low target of $288 is only 6.2% below spot, suggesting limited downside in the sell-side distribution.
- Strong cash generation and low beta: Free cash flow TTM is $9.11 billion against a $73.2 billion market cap, a roughly 12.4% FCF yield, while beta of 0.298 means CI has historically moved at less than a third of the market's volatility. This combination of cash yield and defensiveness is rare in a market where SPY returned 13.13% over the past year versus CI's 0.62%.
- Revenue growth reaccelerating: Q2 2026 revenue of $71.67 billion grew 6.6% year-over-year versus $67.23 billion in Q2 2025, and quarterly revenue has climbed sequentially from $65.50 billion in Q1 2025. Evernorth's PBM scale, anchored by the DoD contract and the Centene win, is driving top-line momentum even as the legacy insurance book is repositioned.
Bearish
- Razor-thin net margins: Net margin is just 2.17% and operating margin 3.32%, with Q2 2026 net income of $1.66 billion on $71.67 billion of revenue. Gross margin of 9.45% (TTM) means a modest reimbursement squeeze or cost trend miss can wipe out a large share of earnings, leaving little buffer.
- Weak liquidity position: The current ratio of 0.849 means current liabilities exceed current assets, and debt-to-equity of 0.754 adds leverage to an already thin-margin model. Interest expense of $356 million in Q2 alone consumes roughly 15.8% of pre-tax income of $2.26 billion, making the company sensitive to refinancing costs.
- Underperformance versus the market: CI has returned just 0.62% over the past year versus SPY's 13.13%, a relative strength of -12.51%, and YTD relative strength is -1.48%. Despite a strong 14.4% one-month rally, the stock has lagged the index over 12 months, reflecting persistent skepticism about the managed-care/PBM model.
- Execution risk from divestitures: The exit from individual exchanges and the strategic review of eviCore introduce restructuring charges and potential revenue leakage, as the Benzinga coverage of the April 2026 guidance raise explicitly flags. Q4 2025 EPS of $4.64 was the weakest quarter in the trailing six, showing earnings volatility around portfolio decisions.
CI Technical Analysis
Beta
0.30
0.30x market volatility
Max Drawdown
-21.4%
Largest decline past year
52-Week Range
$240-$316
Price range past year
Annual Return
-3.5%
Cumulative gain past year
| Period | CI Return | S&P 500 |
|---|---|---|
| 1m | +9.7% | -0.2% |
| 3m | +0.6% | +5.5% |
| 6m | +2.6% | +7.1% |
| 1y | -3.5% | +12.3% |
| ytd | +6.9% | +12.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CI Fundamental Analysis
Quarterly Revenue
$71.7B
2026-06
Revenue YoY Growth
+6.6%
YoY Comparison
Gross Margin
20.9%
Latest Quarter
Free Cash Flow
$9.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CI Overvalued?
PE
12.3x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 8x~22x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are dominated by extreme margin thinness: net margin of 2.17% and operating margin of 3.32% mean that on $71.67 billion of Q2 2026 revenue, a mere 100 basis point deterioration in gross margin (currently 9.45% TTM) would erase roughly $717 million of gross profit, or about 43% of quarterly net income of $1.66 billion. Liquidity is a genuine constraint, with a current ratio of 0.849 and debt-to-equity of 0.754, and interest expense of $356 million per quarter consumes about 15.8% of pre-tax income. Earnings quality is also uneven — Q4 2025 EPS of $4.64 versus Q3 2025's $7.02 shows meaningful quarterly volatility, and the GAAP EPS of $0.08 versus the $46.63 consensus estimate reflects large adjustments between reported and adjusted figures that investors must scrutinize.
Market and competitive risks center on valuation compression and sector sentiment. While a 9.17x forward PE looks cheap, it may be a structural discount reflecting PBM reimbursement pressure flagged across peers (CVS, BTSG) and regulatory scrutiny of drug-pricing spreads. Beta of 0.298 limits macro-driven drawdowns, but it also means CI will likely lag in a broad risk-on rally — already visible in the -12.51% one-year relative strength versus SPY. The April 2026 exit from individual exchanges and eviCore review add execution and headline risk, and the stock's 4.33 short ratio indicates a meaningful bearish cohort positioned for disappointment.
The worst-case scenario is a reimbursement shock combined with a divestiture misstep: Evernorth contract renegotiations compress spreads, eviCore sale proceeds disappoint, and restructuring charges hit earnings just as the individual-exchange exit removes a revenue layer. In that chain, the stock could retest its 52-week low of $239.51, which is 22.0% below the current $306.95, and the historical max drawdown of -21.41% corroborates that a low-20s percentage decline is a realistic adverse outcome. The analyst low target of $288 (-6.2%) is a milder downside marker, but in a true bear case the 52-week low is the more credible floor, implying an investor could lose roughly 22% from current levels.